Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina

摘要

The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03,375,177). Methods NMOSD patients diagnosed according to 2015 criteria and with MOGAD were identified. Patients with at least 3 years of follow-up and periodic clinical evaluations with EDSS outcomes were included. AQP4-antibody and MOG-antibody status was recorded, and patients were stratified as seropositive and seronegative for AQP4-antibody. EDSS of 4, 6, and 7 were defined as dependent variables. Log rank test was used to identify differences between groups. Results Registry data was provided for a total of 137 patients. Of these, seventy-five presented AQP4-ab-positive NMOSD, 45 AQP4-ab-negative NMOSD, and 11 MOGAD. AQP4-ab status was determined by cell-based assay (CBA) in 72% of NMOSD patients. MOG-ab status was tested by CBA in all cases. Mean time to EDSS of 4 was 53.6 +/- 24.5 vs. 63.1 +/- 32.2 vs. 44.7 +/- 32 months in seropositive, seronegative NMOSD, and MOGAD, respectively (p = 0.76). Mean time to EDSS of 6 was 79.2 +/- 44.3 vs. 75.7 +/- 48.6 vs. 54.7 +/- 50 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.23), while mean time to EDSS of 7 was 86.8 +/- 54 vs. 80.4 +/- 51 vs. 58.5 +/- 47 months in seropositive, seronegative NMOSD, and MOGAD (p = 0.39). Conclusion No differences were observed between NMOSD (seropositive and seronegative) and MOGAD in survival curves.